Utilizing Biocatalysis and an Unprecedented Sulfolane-mediated Reductive Acetal Opening to Access Nemtabrutinib from Cyrene

02 November 2022, Version 1

Abstract

The chiral building block 5-amino-2-hydroxymethyltetrahydropyran 1a has been previously synthesized through a cumbersome 9-step synthesis from tri-O-acetyl-D-glucal, which renders access to nemtabrutinib (2), a BTK inhibitor currently being evaluated for the treatment of various hematologic malignancies, inefficient and wasteful. Herein, we describe the development of a protecting group-free, 2-step synthesis of 1a from Cyrene, a biorenewable feedstock. The improved synthesis involves a biocatalytic transamination reaction of Cyrene to install the desired amine-stereocenter in a single step with high diastereoselectivity. The enzymatic reaction is followed by a stereo-retentive reductive acetal opening reaction of the chiral cyrene amine intermediate 3a to furnish 1a. A mechanistic investigation of the acetal opening reaction is also described which uncovered unprecedented reaction conditions for the in-situ generation of diborane mediated by the sulfolane co-solvent. The streamlined synthesis of 1a from Cyrene resulted in a > 27% yield improvement and a significant reduction in the environmental impact of the synthesis.

Keywords

Biocatalysis
Transaminase Enzymes
Reductive Acetal Opening
in-situ Diborane Formation
Sulfolane

Supplementary materials

Title
Description
Actions
Title
Supporting Information
Description
All experimental procedures, reaction optimizations, complete characterization (NMR, MS) for all new compounds, kinetic data and crystallographic data.
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.